BRD4 and neoplasm: The ARV@PDSA Nano‐PROTACs were designed on the basis of the following considerations: i) efficient encapsulation in PDSA nanoparticles to enhance accumulation in targeted cells; ii) redox‐responsive release to improve bioavailability in tumor cells while minimizing off‐target side effects; iii) increased blood circulation time to facilitate the tumor accumulation of ARV@PDSA via the enhanced permeability and retention effect; iv) concomitantly scavenge GSH and in turn reinforce the BRD4 degradation for improved tumor therapy.